CARDIOME PHARMA
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
CARDIOME PHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
1986-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.cardiome.com
Total Employee:
51+
Status:
Active
Contact:
1231231234
Total Funding:
57.01 M USD
Technology used in webpage:
SPF Google Font API Font Awesome Microsoft Exchange Online Office 365 Mail JsDelivr Cloudflare JS CDN JS GoDaddy DNS JQuery CDN
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2013-11-19 | Correvio | Correvio acquired by Cardiome Pharma | N/A |
Investors List
CRG
CRG investment in Post-IPO Debt - Cardiome Pharma
Official Site Inspections
http://www.cardiome.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Cardiome Pharma"
Cardiome Pharma - Crunchbase Company Profile
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will …See details»
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic ...
Mar 20, 2018 Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for …See details»
Cardiome Pharma Corp., Vancouver, British Columbia
Correvio Pharma Corp Completes Strategic Transaction with
May 15, 2018 NASDAQ: CRME TSX: COM Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital. VANCOUVER, May 15, 2018 …See details»
Cardiome Pharma Corp Information - RocketReach
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and …See details»
Cardiome Sells its Canadian Business Portfolio for $25.5 Million ...
May 22, 2018 Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital. Vancouver, BC, May 22, 2018--(T-Net)--Correvio …See details»
Cardiome Pharma Corp. - Vancouver, Canada - bionity.com
Aug 13, 2008 Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous …See details»
Cardiome Pharma Corp. (formerly Nortran Pharmaceuticals)
Cardiome is a research-based biopharmaceutical company dedicated to the discovery and development of new therapies that will improve the health of patients around the world. We …See details»
Cardiome Pharma Corp. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cardiome Pharma Corp. of Richmond, BC. Get the latest business insights from Dun & Bradstreet.See details»
Cardiome - Company Profile - Tracxn
Feb 21, 2025 Cardiome Pharma Corp. carries out product-focused and patient centric research for drug development dedicated to the development and commercialization of treatments for …See details»
Cardiome Pharma Corp. | Cambridge House International
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients …See details»
Organization | Cardiome Pharma
Cardiome Pharma Report issue. For profit Phase 3 Phase 4. Founded: Vancouver Canada ... Organization Overview. First Clinical Trial. 2003 NCT00063687. First Marketed Drug. None …See details»
Cardiome Announces Commercial Launch of BRINAVESS
Jun 12, 2017 Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). ... Organization Profile. Cardiome Pharma Corp. Contact Cision. 866-245 …See details»
Cardiome Makes B.C. Pharma History - BC Business
Jul 7, 2010 Doug Janzen, president and CEO of Cardiome Pharma, saw his company's revenues skyrocket in 2009. Cardiome Pharma Corp.’s headquarters leave no question as to …See details»
Cardiome To Acquire Correvio LLC - Fierce Biotech
Nov 19, 2013 Conference Call. Cardiome will hold a teleconference and webcast to discuss the acquisition of Correvio at 5:00pm EST (2:00pm Pacific) on Monday, November 18th, 2013.See details»
Cardiome Reports Changes To Senior Management Team
May 16, 2017 NASDAQ: CRMETSX: COM VANCOUVER, May 16, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME /TSX: COM) today announced a number of changes to its …See details»
Hi Pat, what is your opinion of Cardiome Pharma?
Nov 15, 2024 Cardiome Pharma, $4.78, symbol COM on Toronto (Shares outstanding: 63.9 million; Market cap: $305.2 million), is a Vancouver-based company that develops …See details»
Cardiome's Biotech Bombshell - BC Business
Jul 1, 2009 When people look back at the few bombshell deals in the Canadian biotech industry this decade, expect to hear a lot about Cardiome-Merck. In April pharmaceutical giant Merck & …See details»
Cardiome shaken by FDA no-go on heart drug refiling
Aug 22, 2017 Cardiome's frustration is understandable given the struggles it has had trying to get Brinavess through the U.S. regulatory pathway. The drug was first filed for approval in …See details»
Cardiome Announces Changes to Senior Management Team
Mar 26, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME) (TSX:COM) today announces changes to the company's senior management team. William Hunter, M.D., previously interim...See details»